InvestorsHub Logo
Followers 33
Posts 2867
Boards Moderated 1
Alias Born 10/24/2015

Re: NY1972 post# 134

Saturday, 03/16/2024 11:47:52 PM

Saturday, March 16, 2024 11:47:52 PM

Post# of 154
AFMD has been hit with the CEO going, and CMO acting as the interim, both the CSO and CFO resigning, and R/S. Let's hope the data is positive as times remain tough in the NK field. If so, investors should probably expect a cash raise.

As for NKTX, hope they start selecting optimal donors and testing ML NKs, especially for solid tumours https://aacrjournals.org/clincancerres/article/27/17/4859/671641/Memory-like-Differentiation-Enhances-NK-Cell https://aacrjournals.org/cancerres/article/83/7_Supplement/893/719928/Abstract-893-Memory-like-differentiation-enhances